Original Article

You have full text access to this OnlineOpen article

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

  1. Levi S. Downs Jr. MD1,†,*,
  2. Patricia L. Judson MD1,
  3. Peter A. Argenta MD1,
  4. Rahel Ghebre MD1,
  5. Melissa A. Geller MD1,
  6. Robin L. Bliss MS2,
  7. Matthew P. Boente MD3,
  8. William A. Nahhas MD4,
  9. Samir Z. Abu-Ghazaleh MD5,
  10. M. Dwight Chen MD6,
  11. Linda F. Carson MD1

Article first published online: 30 NOV 2007

DOI: 10.1002/cncr.23164

Issue

Cancer

Cancer

Volume 112, Issue 2, pages 331–339, 15 January 2008

Additional Information

How to Cite

Downs, L. S., Judson, P. L., Argenta, P. A., Ghebre, R., Geller, M. A., Bliss, R. L., Boente, M. P., Nahhas, W. A., Abu-Ghazaleh, S. Z., Chen, M. D. and Carson, L. F. (2008), A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer, 112: 331–339. doi: 10.1002/cncr.23164

Author Information

  1. 1

    Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota

  2. 2

    University of Minnesota Cancer Center, Minneapolis, Minnesota

  3. 3

    Department of Gynecologic Oncology, Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota

  4. 4

    Division of Gynecologic Oncology, Wright State University Miami Valley Hospital, Dayton, Ohio

  5. 5

    Division of Gynecologic Oncology, Avera Cancer Institute, Sioux Falls, South Dakota

  6. 6

    Center for Gynecologic Oncology and Pelvic Surgery, Mountain View, California

  1. †

    Fax: (612) 626-0665.

*Obstetrics, Gynecology, and Women's Health, University of Minnesota, 420 Delaware Street SE, MMC 395, Minneapolis, MN 55455

Publication History

  1. Issue published online: 4 JAN 2008
  2. Article first published online: 30 NOV 2007
  3. Manuscript Accepted: 10 AUG 2007
  4. Manuscript Revised: 3 AUG 2007
  5. Manuscript Received: 13 JUN 2007

Funded by

  • Celgene Corporation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (137K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jori S. Carter, Levi S. Downs, A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma, International Journal of Clinical Oncology, 2011, 16, 6, 666

    CrossRef

  2. 2
    Maurizio Chiriva-Internati, Leonardo Mirandola, W. Martin Kast, Marjorie R. Jenkins, Everardo Cobos, Martin J. Cannon, Understanding the Cross-Talk between Ovarian Tumors and Immune Cells: Mechanisms for Effective Immunotherapies, International Reviews of Immunology, 2011, 30, 2-3, 71

    CrossRef

  3. 3
    Francois P. Duhoux, Jean-Pascal Machiels, Antivascular Therapy for Epithelial Ovarian Cancer, Journal of Oncology, 2010, 2010, 1

    CrossRef

  4. 4
    Aarati Ranganathan, Marissa Shrader, The 41st Annual Meeting on Women's Cancer Conducted by the Society of Gynecologic Oncologists, Clinical Ovarian Cancer, 2010, 3, 1, 9

    CrossRef

  5. 5
    B. Schmalfeldt, A. Burges, P. Harter, „Targeted therapy“ des Ovarialkarzinoms, Der Gynäkologe, 2009,

    CrossRef

  6. 6
    Jalid Sehouli, Gülten Oskay-Özcelik, Current role and future aspects of topotecan in relapsed ovarian cancer, Current Medical Research and Opinion, 2009, 25, 3, 639

    CrossRef

  7. 7
    Ernest S. Han, Paul Lin, Mark Wakabayashi, Current Status on Biologic Therapies in the Treatment of Epithelial Ovarian Cancer, Current Treatment Options in Oncology, 2009, 10, 1-2, 54

    CrossRef

  8. 8
    Ritu Salani, Floor J Backes, Larry J Copeland, Overview of epithelial ovarian cancer and updates in management strategies, Expert Review of Obstetrics & Gynecology, 2009, 4, 4, 383

    CrossRef

View Full Article (HTML) Get PDF (137K)